Table 3.
The main pharmacokinetic parameters of tofacitinib in the two groups (n = 6, mean ± SD).
| Pharmacokinetics parameters | Experimental group | Control group |
|---|---|---|
| AUC(0–t) (ng/mL/h) | 2016.27 ± 481.62* | 1222.81 ± 222.07 |
| AUC(0–∞) (ng/mL/h) | 2198.85 ± 604.38* | 1245.16 ± 201.52 |
| MRT(0–t) (h) | 6.57 ± 0.66* | 4.90 ± 0.51 |
| MRT(0–∞) (h) | 8.71 ± 2.17* | 5.45 ± 1.06 |
| t1/2 (h) | 6.30 ± 2.51 | 4.08 ± 1.92 |
| Tmax (h) | 3.00 ± 0.00* | 0.75 ± 0.29 |
| Vz (L/kg) | 21.16 ± 8.66 | 25.55 ± 16.08 |
| CL (L/h/kg) | 2.42 ± 0.70* | 4.10 ± 0.72 |
| Cmax (ng/mL) | 281.84 ± 34.14 | 221.33 ± 54.23 |
AUC: area under the plasma concentration–time curve; CL: plasma clearance; Cmax: maximum plasma concentration; MRT: mean residence time; SD: standard deviation; t1/2: half-life; Tmax: maximum plasma time.
*
p < 0.05 indicates significant differences from the control.